These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26208334)

  • 1. Evaluation of a pharmacist-run antiarrhythmic clinic in an ambulatory practice.
    Lifer SM; Musser MR; Kier KL
    J Am Pharm Assoc (2003); 2015; 55(5):546-51. PubMed ID: 26208334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review.
    Snider M; Kalbfleisch S; Carnes CA
    Clin Ther; 2009 Jun; 31(6):1209-18. PubMed ID: 19695388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a pharmacist-managed electrolyte protocol in outpatients on antiarrhythmic medications.
    Long VP; Carnes CA; Vecchiet J; Houmsse M; Hirsch A; Snider MJ
    J Am Pharm Assoc (2003); 2017; 57(4):526-531. PubMed ID: 28610942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a pharmacist-managed amiodarone monitoring program.
    Spence MM; Polzin JK; Weisberger CL; Martin JP; Rho JP; Willick GH
    J Manag Care Pharm; 2011 Sep; 17(7):513-22. PubMed ID: 21870892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-benefit and cost-savings analyses of antiarrhythmic medication monitoring.
    Snider M; Carnes C; Grover J; Davis R; Kalbfleisch S
    Am J Health Syst Pharm; 2012 Sep; 69(18):1569-73. PubMed ID: 22935939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
    Kim MH; Smith PJ; Jhaveri M; Lin J; Klingman D
    Clin Ther; 2011 Nov; 33(11):1668-1681.e1. PubMed ID: 22108302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement.
    Finks SW; Rogers KC; Manguso AH
    Int J Pharm Pract; 2011 Aug; 19(4):281-6. PubMed ID: 21733016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a program for outpatient sotalol loading with physician and pharmacist monitoring.
    Roberts C; Sherry M; Labreck M; Amin A; Sullivan D
    J Am Pharm Assoc (2003); 2022; 62(5):1700-1706. PubMed ID: 35725728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review.
    Dixon DL; Dunn SP; Kelly MS; McLlarky TR; Brown RE
    Pharmacotherapy; 2016 Feb; 36(2):230-6. PubMed ID: 26846446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned.
    Vijayalakshmi K; Whittaker VJ; Sutton A; Campbell P; Wright RA; Hall JA; Harcombe AA; Linker NJ; Stewart MJ; Davies A; de Belder MA
    Am Heart J; 2006 Apr; 151(4):863.e1-6. PubMed ID: 16569550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of an amiodarone ambulatory care clinic.
    Tafreshi J; Chui MA; Riley AB
    Am J Health Syst Pharm; 2009 Nov; 66(22):1997-8, 2000-1. PubMed ID: 19890081
    [No Abstract]   [Full Text] [Related]  

  • 13. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
    Joseph AP; Ward MR
    Ann Emerg Med; 2000 Jul; 36(1):1-9. PubMed ID: 10874228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
    Mason JW
    N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a pharmacist-led outpatient direct oral anticoagulant service.
    Ashjian E; Kurtz B; Renner E; Yeshe R; Barnes GD
    Am J Health Syst Pharm; 2017 Apr; 74(7):483-489. PubMed ID: 28336758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
    Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
    Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution.
    Gauthier TP; Moreira E; Chan C; Cabrera A; Toro M; Carrasquillo MZ; Corentin M; Sherman EM
    J Am Pharm Assoc (2003); 2016; 56(6):670-676. PubMed ID: 27667501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J
    Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 4 years of clinical pharmacist anticoagulation case management in a rural, private physician office.
    Ernst ME; Brandt KB
    J Am Pharm Assoc (2003); 2003; 43(5):630-6. PubMed ID: 14626756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.